Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FGEQ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,365
Award facts
- Contract value 100% obligated
- $12,364.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc. for the supply of JAKAFI 10 mg tablets (60-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this delivery order on December 30, 2025, with an ultimate completion date of December 31, 2025. The award carried no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR, which was established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's IDC, awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, comprising a 30-month base period with three optional 30-month renewal periods. The delivery order for JAKAFI reflects the company's role as a critical pharmaceutical supplier fulfilling diverse and specialized medication requirements across the federal military medical system, with the contractor demonstrating substantial performance capability through numerous prior delivery orders spanning oncology treatments, immunosuppressants, biologics, vaccines, and routine pharmaceuticals.
Quick answers
Who was awarded contract SPE2DR26FGEQ8?
SPE2DR26FGEQ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FGEQ8 worth?
The government has obligated $12,365 on SPE2DR26FGEQ8.
Is contract SPE2DR26FGEQ8 an order under another contract?
Yes. SPE2DR26FGEQ8 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGEQ8 competed?
The extent of competition for SPE2DR26FGEQ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award